Several key areas in gastroenterology pharmacotherapy are rapidly evolving, including the treatment of hepatitis C virus (HCV), irritable bowel syndrome, gastroesophageal reflux disease (GERD) and peptic ulcer disease. HCV treatment has radically changed in the past 2 years and now most patients are treatment candidates and have a high likelihood of permanent cure. Pharmacotherapy is now first-line treatment for patients with moderate to severe symptoms of irritable bowel syndrome. Proton pump inhibitors (PPIs) are the mainstay of therapy in gastric and duodenal ulcers and GERD, although long-term use carries the risk of several side effects that should be considered
Irritable bowel syndrome (IBS) is a highly prevalent functional disorder characterised by chronic an...
Irritable bowel syndrome (IBS) is one of the most common gut functional diseases, affecting 10-20% o...
Proton pump inhibitors (PPIs) are very effective in maintaining symptomatic and endoscopic remission...
There have been a number of exciting advancements and changes in the gastroenterology field over the...
Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal tract of unk...
Irritable bowel syndrome with constipation and chronic functional constipation are common digestive ...
The subjects covered in this chapter are the agents used for the control of acidity, prokinetics (wh...
A new generation of PPI are presently in clinical trials. They are characterized by a quicker and lo...
Irritable bowel syndrome is a functional bowel disorder with gastrointestinal symptoms (e.g. abdomin...
As a physiologic milieu, there is none so inhospitable as the human stomach. Over the course of a li...
Acid-related disorders of the upper gastrointestinal tract are the most important indications for tr...
Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gast...
Proton pump inhibitors have changed the management of acid-related upper gastrointestinal disorders....
Proton pump inhibitors (PPIs) are medications that suppress the production of stomach acid.1 Introdu...
The treatment of reflux disease did not changed. PPI treatment remains the first line treatment and ...
Irritable bowel syndrome (IBS) is a highly prevalent functional disorder characterised by chronic an...
Irritable bowel syndrome (IBS) is one of the most common gut functional diseases, affecting 10-20% o...
Proton pump inhibitors (PPIs) are very effective in maintaining symptomatic and endoscopic remission...
There have been a number of exciting advancements and changes in the gastroenterology field over the...
Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal tract of unk...
Irritable bowel syndrome with constipation and chronic functional constipation are common digestive ...
The subjects covered in this chapter are the agents used for the control of acidity, prokinetics (wh...
A new generation of PPI are presently in clinical trials. They are characterized by a quicker and lo...
Irritable bowel syndrome is a functional bowel disorder with gastrointestinal symptoms (e.g. abdomin...
As a physiologic milieu, there is none so inhospitable as the human stomach. Over the course of a li...
Acid-related disorders of the upper gastrointestinal tract are the most important indications for tr...
Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gast...
Proton pump inhibitors have changed the management of acid-related upper gastrointestinal disorders....
Proton pump inhibitors (PPIs) are medications that suppress the production of stomach acid.1 Introdu...
The treatment of reflux disease did not changed. PPI treatment remains the first line treatment and ...
Irritable bowel syndrome (IBS) is a highly prevalent functional disorder characterised by chronic an...
Irritable bowel syndrome (IBS) is one of the most common gut functional diseases, affecting 10-20% o...
Proton pump inhibitors (PPIs) are very effective in maintaining symptomatic and endoscopic remission...